StreetInsider.com News Articles

Form 4 PERRIGO Co plc For: Mar 06 Filed by: Willis Robert

Tue, 10 Mar 2026 14:24:00 -0400

si-local-file:///var/storage/secattach/20260310/26138574.html

Form 4 PERRIGO Co plc For: Mar 06 Filed by: Willis Robert

Tue, 10 Mar 2026 14:24:00 -0400

si-local-file:///var/storage/secattach/20260310/26138574.html

Form 4 PERRIGO Co plc For: Mar 06 Filed by: Lockwood-Taylor Patrick

Tue, 10 Mar 2026 14:01:00 -0400

si-local-file:///var/storage/secattach/20260310/26138429.html

Form 4 PERRIGO Co plc For: Mar 06 Filed by: Lockwood-Taylor Patrick

Tue, 10 Mar 2026 14:01:00 -0400

si-local-file:///var/storage/secattach/20260310/26138429.html

Form 4 PERRIGO Co plc For: Mar 06 Filed by: Samuelson Jonas

Tue, 10 Mar 2026 13:56:00 -0400

si-local-file:///var/storage/secattach/20260310/26138395.html

Form 4 PERRIGO Co plc For: Mar 06 Filed by: Samuelson Jonas

Tue, 10 Mar 2026 13:56:00 -0400

si-local-file:///var/storage/secattach/20260310/26138395.html

Form 4 PERRIGO Co plc For: Mar 06 Filed by: Bezerra Eduardo Guarita

Tue, 10 Mar 2026 11:49:00 -0400

si-local-file:///var/storage/secattach/20260310/26137804.html

Form 4 PERRIGO Co plc For: Mar 06 Filed by: Bezerra Eduardo Guarita

Tue, 10 Mar 2026 11:49:00 -0400

si-local-file:///var/storage/secattach/20260310/26137804.html

Perrigo to Present at the UBS Global Consumer and Retail Conference

Tue, 03 Mar 2026 16:30:00 -0400

DUBLIN, Ireland, March 3, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of consumer products, today announced that President and CEO Patrick Lockwood-Taylor is scheduled to present at the UBS Global Consumer and Retail Conference, on Wednesday, March 11th at 11:00 AM EDT.

Perrigo to Present at the UBS Global Consumer and Retail Conference

Tue, 03 Mar 2026 16:30:00 -0400

Perrigo to Present at the UBS Global Consumer and Retail Conference

Tue, 03 Mar 2026 16:30:00 -0400

Perrigo to Present at the UBS Global Consumer and Retail Conference

Tue, 03 Mar 2026 16:30:00 -0400

Perrigo Co. (PRGO) PT Lowered to $15 at JPMorgan

Fri, 27 Feb 2026 09:17:43 -0400

JPMorgan analyst Chris Schott lowered the price target on Perrigo Co. (NYSE: PRGO) to $15.00 (from $18.00) while maintaining a Neutral rating.

Perrigo Co. (PRGO) PT Lowered to $17 at Canaccord

Fri, 27 Feb 2026 06:44:38 -0400

Canaccord analyst Susan Anderson lowered the price target on Perrigo Co. (NYSE: PRGO) to $17.00 (from $20.00) while maintaining a Buy rating.

Form 10-K PERRIGO Co plc For: Dec 31

Thu, 26 Feb 2026 13:35:00 -0400

si-local-file:///var/storage/secattach/20260226/26068517.html

Form 10-K PERRIGO Co plc For: Dec 31

Thu, 26 Feb 2026 13:35:00 -0400

si-local-file:///var/storage/secattach/20260226/26068517.html

Jefferies on Perrigo Co. (PRGO): '4Q'25 EPS First Take: '26 a Reset Year'

Thu, 26 Feb 2026 10:34:24 -0400

Jefferies analyst Keith Devas reiterated a Hold rating and $18.00 price target on Perrigo Co. (NYSE: PRGO).

The analyst comments "Roughly in-line 4Q results overshadow a business searching for more stable footing. In '26, soft OTC trends and formula inventory headwinds will weigh heavily on results. Some of these pressures are temporary, and although final plans for formula are still unclear, expectations for a better 2H with a simpler business model may bode well for '27. A lot can happen, making execution critical. Progress will need be judged quarter by quarter."

For an analyst ratings summary and ratings history on Perrigo Co.

Form 8-K PERRIGO Co plc For: Feb 26

Thu, 26 Feb 2026 06:38:00 -0400

si-local-file:///var/storage/secattach/20260226/26063883.html

Form 8-K PERRIGO Co plc For: Feb 26

Thu, 26 Feb 2026 06:38:00 -0400

si-local-file:///var/storage/secattach/20260226/26063883.html

Perrigo (PRGO) Misses Q4 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance

Thu, 26 Feb 2026 06:34:47 -0400

Perrigo (NYSE: PRGO) reported Q4 EPS of $0.77, $0.02 worse than the analyst estimate of $0.79. Revenue for the quarter came in at $1.11 billion versus the consensus estimate of $1.1 billion.

GUIDANCE:

Perrigo sees FY2026 EPS of $2.25-$2.55.

For earnings history and earnings-related data on Perrigo (PRGO) click here.

Perrigo (PRGO) Misses Q4 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance

Thu, 26 Feb 2026 06:34:47 -0400

Perrigo (NYSE: PRGO) reported Q4 EPS of $0.77, $0.02 worse than the analyst estimate of $0.79. Revenue for the quarter came in at $1.11 billion versus the consensus estimate of $1.1 billion.

GUIDANCE:

Perrigo sees FY2026 EPS of $2.25-$2.55.

For earnings history and earnings-related data on Perrigo (PRGO) click here.

Perrigo Reports Fourth Quarter and Fiscal Year 2025 Financial Results From Continuing Operations

Thu, 26 Feb 2026 06:31:00 -0400

Delivered FY2025 Adj. EPS at the Midpoint of Updated Outlook Range

Advanced '3-S Plan' with Perrigo Store Brand OTC and Key Brands Gaining Share1,2 in 2025, Despite Soft Category Consumption

Launching New Operational Enhancement Program - Expected to Deliver Pre-Tax Annualized Savings of $80 million to $100 million

Transitioning to New Reporting Segments Beginning Q1 2026, Aligned to Commercial Operating Model

Issues FY2026 'All In' Outlook; Introduces FY2026 'CORE' Outlook, which Excludes Infant Formula and Previously Announced Divestitures

Fourth Quarter 2025 YoY Highlights:

Net Sales: $1.11 billion, -2.5% year-over-year as favorable FX +2.3% was more than offset by organic net sales -4.5% and the impact of divestitures and exited products -0.4%.
Organic Net Sales: Down due primarily to -2.9% from Infant Formula. The rest of the business was down -1.6%, half of which stemmed from lower OTC contract manufacturing and the

Perrigo Reports Fourth Quarter and Fiscal Year 2025 Financial Results From Continuing Operations

Thu, 26 Feb 2026 06:31:00 -0400

Delivered FY2025 Adj. EPS at the Midpoint of Updated Outlook Range
Advanced '3-S Plan' with Perrigo Store Brand OTC and Key Brands Gaining Share1,2 in 2025, Despite Soft Category Consumption
Launching New Operational Enhancement Program - Expected to Deliver Pre-Tax Annualized Savings of $80 million to $100 million
Transitioning to New Reporting Segments Beginning Q1 2026, Aligned to Commercial Operating Model
Issues FY2026 'All In' Outlook; Introduces FY2026 'CORE' Outlook, which Excludes Infant Formula and Previously Announced Divestitures
Fourth Quarter 2025 YoY Highlights:
Net Sales: $1.11 billion, -2.5% year-over-year as favorable FX +2.3% was more than offset by organic net sales -4.5% and the impact of divestitures and exited products -0.4%.
Organic Net Sales: Down due primarily to -2.9% from Infant Formula. The rest of the business was down -1.6%, half of which stemmed from lower OTC contract manufacturing and the

Perrigo Reports Fourth Quarter and Fiscal Year 2025 Financial Results From Continuing Operations

Thu, 26 Feb 2026 06:31:00 -0400

Delivered FY2025 Adj. EPS at the Midpoint of Updated Outlook Range
Advanced '3-S Plan' with Perrigo Store Brand OTC and Key Brands Gaining Share1,2 in 2025, Despite Soft Category Consumption
Launching New Operational Enhancement Program - Expected to Deliver Pre-Tax Annualized Savings of $80 million to $100 million
Transitioning to New Reporting Segments Beginning Q1 2026, Aligned to Commercial Operating Model
Issues FY2026 'All In' Outlook; Introduces FY2026 'CORE' Outlook, which Excludes Infant Formula and Previously Announced Divestitures
Fourth Quarter 2025 YoY Highlights:
Net Sales: $1.11 billion, -2.5% year-over-year as favorable FX +2.3% was more than offset by organic net sales -4.5% and the impact of divestitures and exited products -0.4%.
Organic Net Sales: Down due primarily to -2.9% from Infant Formula. The rest of the business was down -1.6%, half of which stemmed from lower OTC contract manufacturing and the

Perrigo Reports Fourth Quarter and Fiscal Year 2025 Financial Results From Continuing Operations

Thu, 26 Feb 2026 06:31:00 -0400

Delivered FY2025 Adj. EPS at the Midpoint of Updated Outlook Range
Advanced '3-S Plan' with Perrigo Store Brand OTC and Key Brands Gaining Share1,2 in 2025, Despite Soft Category Consumption
Launching New Operational Enhancement Program - Expected to Deliver Pre-Tax Annualized Savings of $80 million to $100 million
Transitioning to New Reporting Segments Beginning Q1 2026, Aligned to Commercial Operating Model
Issues FY2026 'All In' Outlook; Introduces FY2026 'CORE' Outlook, which Excludes Infant Formula and Previously Announced Divestitures
Fourth Quarter 2025 YoY Highlights:
Net Sales: $1.11 billion, -2.5% year-over-year as favorable FX +2.3% was more than offset by organic net sales -4.5% and the impact of divestitures and exited products -0.4%.
Organic Net Sales: Down due primarily to -2.9% from Infant Formula. The rest of the business was down -1.6%, half of which stemmed from lower OTC contract manufacturing and the